首页> 外国专利> ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS

ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS

机译:晚期癌症患者的活化树突状细胞成分和免疫治疗

摘要

The present disclosure provides partially mature and activated dendritic cells that produce levels of cytokines/chemokines, for example, one or any combination of, and/or all of IL-6, IL-8, IL-12 and/or TNFα, that are correlated with improved clinical outcomes, significantly increased survival times and significantly increased times to tumor or cancer recurrence. The determined threshold amounts of these cytokines can be used for (i) a immunotherapeutic potency test for activated dendritic cells, (ii) selecting responder patients, (iii) rejecting non-responder patients, and (iv) to screen for dendritic cell activation or maturation agents that can also induce the production of the threshold amount of the cytokines/chemokines.
机译:本发明提供了部分成熟和活化的树突状细胞,其产生细胞因子/趋化因子水平,例如,IL-6、IL-8、IL-12和/或TNFα的一种或任何组合和/或全部,与改善的临床结果、显著增加的生存时间和显著增加的肿瘤或癌症复发时间相关。确定的这些细胞因子的阈值量可用于(i)激活的树突状细胞的免疫治疗效力试验,(ii)选择应答者患者,(iii)拒绝非应答者患者,以及(iv)筛选也可诱导产生阈值量的细胞因子/趋化因子的树突状细胞激活剂或成熟剂。

著录项

  • 公开/公告号EP3971285A2

    专利类型

  • 公开/公告日2022-03-23

    原文格式PDF

  • 申请/专利权人 NORTHWEST BIOTHERAPEUTICS INC.;

    申请/专利号EP20210189488

  • 发明设计人 BOSCH MARNIX L.;

    申请日2016-09-14

  • 分类号C12N5/0784;C12N5/02;C07K14/535;C07K14/54;C07K14/57;C07K14/525;A61K35/15;G01N33/50;G01N33/569;G01N33/68;

  • 国家 EP

  • 入库时间 2022-08-25 00:02:13

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号